title: Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
authors.affiliation: Hematology Department, Institut Paoli Calmettes, Marseille, France; Aix-Marseille University, Medecine Faculty, Marseille, France.
authors.forename: Raynier
authors.initials: R
authors.lastname: Devillier
authors.forename: Sarah
authors.initials: S
authors.lastname: Bertoli
authors.forename: Thomas
authors.initials: T
authors.lastname: Prébet
authors.forename: Françoise
authors.initials: F
authors.lastname: Huguet
authors.forename: Anne
authors.initials: A
authors.lastname: Etienne
authors.forename: Aude
authors.initials: A
authors.lastname: Charbonnier
authors.forename: Jérôme
authors.initials: J
authors.lastname: Rey
authors.forename: Eric
authors.initials: E
authors.lastname: Delabesse
authors.forename: Evelyne
authors.initials: E
authors.lastname: D'Incan
authors.forename: Anne
authors.initials: A
authors.lastname: Huynh
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Christian
authors.initials: C
authors.lastname: Récher
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D020732:Cytogenetic Analysis; D003630:Daunorubicin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin